JP2007508242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508242A5 JP2007508242A5 JP2006522433A JP2006522433A JP2007508242A5 JP 2007508242 A5 JP2007508242 A5 JP 2007508242A5 JP 2006522433 A JP2006522433 A JP 2006522433A JP 2006522433 A JP2006522433 A JP 2006522433A JP 2007508242 A5 JP2007508242 A5 JP 2007508242A5
- Authority
- JP
- Japan
- Prior art keywords
- thromboxane
- receptor antagonist
- cox
- inhibitor
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims description 45
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims description 44
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 229960003422 indobufen Drugs 0.000 claims description 20
- AYDXAULLCROVIT-UHFFFAOYSA-N indobufen Chemical compound C1=CC(C(C(O)=O)CC)=CC=C1N1C(=O)C2=CC=CC=C2C1 AYDXAULLCROVIT-UHFFFAOYSA-N 0.000 claims description 20
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 20
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 20
- 150000003180 prostaglandins Chemical class 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims description 17
- 229950004274 ifetroban Drugs 0.000 claims description 17
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000008331 benzenesulfonamides Chemical class 0.000 claims description 9
- 230000002195 synergetic effect Effects 0.000 claims description 8
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 7
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 7
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 7
- 206010047249 Venous thrombosis Diseases 0.000 claims description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 7
- 229960002390 flurbiprofen Drugs 0.000 claims description 7
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000905 indomethacin Drugs 0.000 claims description 7
- 229960004752 ketorolac Drugs 0.000 claims description 7
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 7
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 7
- 229960003464 mefenamic acid Drugs 0.000 claims description 7
- 229960004270 nabumetone Drugs 0.000 claims description 7
- 229960002009 naproxen Drugs 0.000 claims description 7
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 7
- 229960002739 oxaprozin Drugs 0.000 claims description 7
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 206010010904 Convulsion Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 description 33
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229960005293 etodolac Drugs 0.000 description 5
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 5
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical group C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000003259 prostaglandin group Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49297503P | 2003-08-07 | 2003-08-07 | |
| PCT/IB2004/002523 WO2005016334A1 (en) | 2003-08-07 | 2004-08-05 | Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508242A JP2007508242A (ja) | 2007-04-05 |
| JP2007508242A5 true JP2007508242A5 (https=) | 2007-09-20 |
Family
ID=34193159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522433A Withdrawn JP2007508242A (ja) | 2003-08-07 | 2004-08-05 | トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050059741A1 (https=) |
| EP (1) | EP1660076A1 (https=) |
| JP (1) | JP2007508242A (https=) |
| AU (1) | AU2004264722A1 (https=) |
| CA (1) | CA2534316A1 (https=) |
| WO (1) | WO2005016334A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK471479A (da) * | 1978-12-13 | 1980-06-14 | Pfizer | Fremgangsmaade til fremstilling af imidazolderivater og salte deraf |
| US5100889A (en) * | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| ZA911453B (en) * | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
| GB9220137D0 (en) * | 1992-09-23 | 1992-11-04 | Pfizer Ltd | Therapeutic agents |
| JPH0753505A (ja) * | 1992-10-01 | 1995-02-28 | Hokuriku Seiyaku Co Ltd | ベンゼンスルホンアミド誘導体及びその用途 |
| US5605917A (en) * | 1994-12-22 | 1997-02-25 | Bristol-Myers Squibb Company | Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US6586458B1 (en) * | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| AU2890899A (en) * | 1998-03-13 | 1999-09-27 | Pozen, Inc. | Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists |
| AU2001264729A1 (en) * | 2000-05-22 | 2001-12-03 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
| SI1429807T1 (sl) * | 2001-09-19 | 2007-08-31 | Nycomed Gmbh | Kombinacija NSAID in PDE-4 inhibitorja |
| CN1665538A (zh) * | 2002-07-09 | 2005-09-07 | B·M·R·A·有限公司 | 血栓烷a2受体拮抗剂和cox－2抑制剂的药物组合 |
-
2004
- 2004-08-05 EP EP04744172A patent/EP1660076A1/en not_active Withdrawn
- 2004-08-05 AU AU2004264722A patent/AU2004264722A1/en not_active Abandoned
- 2004-08-05 CA CA002534316A patent/CA2534316A1/en not_active Abandoned
- 2004-08-05 WO PCT/IB2004/002523 patent/WO2005016334A1/en not_active Ceased
- 2004-08-05 US US10/911,644 patent/US20050059741A1/en not_active Abandoned
- 2004-08-05 JP JP2006522433A patent/JP2007508242A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080113973A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
| JP2005533830A5 (https=) | ||
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| Krasniqi et al. | Analgesics use in dentistry | |
| AU2009201201A1 (en) | Novel pharmaceutical composition | |
| US20260102370A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| Seymour | Drug interactions in dentistry | |
| JP2007508242A5 (https=) | ||
| JP2011514354A5 (https=) | ||
| AU2015274895A1 (en) | Fixed dose combination for pain relief without edema | |
| ES2811904T3 (es) | Composición farmacéutica que comprende bisoprolol y perindopril | |
| JP2011525479A (ja) | 非ステロイド性抗炎症性化合物と降圧化合物とを組み合わせた製剤処方及びその使用方法 | |
| JP2007508242A (ja) | トロンボキサンａ２受容体アンタゴニストとシクロオキシゲネーゼ−１の阻害剤との組み合わせを伴う組成物および方法 | |
| RU2530628C1 (ru) | Фармацевтическая композиция и набор для лечения и/или предупреждения нарушений, связанных с ожирением, и способ лечения и/или предупреждения нарушений, связанных с ожирением | |
| RU2423979C2 (ru) | Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей | |
| BRMU8603054U2 (pt) | embalagem ou kit de medicamentos ou apresentaÇço para a administraÇço harmoniosa de medicamentos no tratamento da hipertensço, da angina e de outros tipos de doenÇas cardiovasculares | |
| Schmidt | Focus on K-Fenak Anti-Inflammatory® tablets | |
| WO2024221023A1 (en) | Anti-inflammatory, analgesic and antipyretic suppository | |
| WO2007093020A1 (en) | Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation. | |
| US20210179623A1 (en) | New chemical compound containing active enantiometer s-(-) ketorolac tromethamine for the treatment of pain | |
| Borins | Homeopathic remedies: scepticism abounds | |
| WO2012011118A2 (en) | Development of a fixed dose combination dosage form containing ramipril and carvedilol | |
| Standard et al. | NITROLINGUAL® PUMPSPRAY | |
| HK1080750A (en) | Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor | |
| WO2004108056A2 (en) | Packing, or kit of medicaments, or facilitating presentation of administering of medicaments on the part of individuals under preventive situation and/or treatment of the atherosclerosis disease |